Lupin receives USFDA approval of sNDA for SOLOSEC?

17 Feb 2022 , 06:58 PM

Lupin announced that the U.S. Food and Drug Administration has approved the companys supplemental New Drug Application (sNDA) to expand the use of SOLOSEC? (secnidazole) in the treatment of bacterial vaginosis (BV) for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years of age and older. Bacterial vaginosis is a common vaginal infection and trichomoniasis is the most common non-viral, curable sexually transmitted infection in the U.S. The supplemental adolescent approval enhances SOLOSECs? strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV.

Powered by Capital Market – Live News